Roche Sees Glass Half Full After Ipatasertib Data
Hit One Co-Primary Endpoint, Missed The Other
Executive Summary
Roche’s ipatasertib has improved progression-free survival in a sub-group of previously untreated metastatic castration-resistant prostate cancer patients – those whose tumors had PTEN loss – in a Phase III study. However the AKT inhibitor failed to cut the risk of disease worsening or death in the broader population.
You may also be interested in...
Roche’s Ipatasertib Promising In Prostate, But Disappointing In Breast Cancer
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.
Array's Three Value Drivers Align With Pfizer's Three Oncology Pillars In $11.4bn Deal
Pfizer is buying Array for a 62% premium, citing its Braftovi/Mektovi drug combo, pipeline of targeted cancer therapies and royalty revenue from partnered assets as key value drivers, aligning with the three pillars the big pharma recently outlined for its oncology strategy.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.